Adam B. Salmon

Aging Cell 2013

Open access · CC-BY

Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

▲ 647

Aging Cell 2016

Open access · CC-BY

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer

▲ 387

The FASEB Journal 2009

Preprint · OA

Increased superoxide in vivo accelerates age‐associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration

▲ 294

PLoS ONE 2014

Open access · CC0

Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major Changes in the Liver Transcriptome

▲ 151

JCI Insight 2020

Open access · CC-BY

Canagliflozin extends life span in genetically heterogeneous male but not female mice

▲ 128

Aging Cell 2022

Open access · CC-BY

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

▲ 73

Science 2012

Preprint · OA

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

▲ 69

Aging 2014

Open access · CC-BY

Rapamycin-induced metabolic defects are reversible in both lean and obese mice

▲ 68

The Journals of Gerontology Series A 2012

Open access · CC-BY

Short-Term Treatment With Rapamycin and Dietary Restriction Have Overlapping and Distinctive Effects in Young Mice

▲ 68

Aging 2015

Open access · CC-BY

Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)

▲ 50

GeroScience 2021

Open access · OA

DNA methylation age analysis of rapamycin in common marmosets

▲ 43

The Journals of Gerontology Series A 2014

Open access · OA

Rapamycin and Dietary Restriction Induce Metabolically Distinctive Changes in Mouse Liver

▲ 41

The Journals of Gerontology Series A 2019

Open access · CC-BY

Is Rapamycin a Dietary Restriction Mimetic?

▲ 41

GeroScience 2022

Open access · CC-BY

Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice

▲ 33

Pathobiology of Aging & Age-related Diseases 2016

Open access · CC-BY

Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate

▲ 29

GeroScience 2024

Preprint · OA

Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin

▲ 28

Scientific Reports 2022

Open access · CC-BY

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice

▲ 23

Pathobiology of Aging & Age-related Diseases 2019

Open access · CC-BY

Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset

▲ 20

Longevity & Healthspan 2012

Open access · CC-BY

Thioredoxin, oxidative stress, cancer and aging

▲ 20

GeroScience 2023

Preprint · OA

Testing the evidence that lifespan-extending compound interventions are conserved across laboratory animal model species

▲ 14

bioRxiv (Cold Spring Harbor Laboratory) 2020

Preprint · OA

Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice

▲ 12

bioRxiv (Cold Spring Harbor Laboratory) 2021

Preprint · CC-BY

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate slows aging in mice

▲ 0

Collaborators

Works in the record

Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer

Increased superoxide in vivo accelerates age‐associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration

Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major Changes in the Liver Transcriptome

Canagliflozin extends life span in genetically heterogeneous male but not female mice

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

Rapamycin-induced metabolic defects are reversible in both lean and obese mice

Short-Term Treatment With Rapamycin and Dietary Restriction Have Overlapping and Distinctive Effects in Young Mice

Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)

DNA methylation age analysis of rapamycin in common marmosets

Rapamycin and Dietary Restriction Induce Metabolically Distinctive Changes in Mouse Liver

Is Rapamycin a Dietary Restriction Mimetic?

Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice

Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate

Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice

Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset

Thioredoxin, oxidative stress, cancer and aging

Testing the evidence that lifespan-extending compound interventions are conserved across laboratory animal model species

Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate slows aging in mice